Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis